Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy-Reference-Cited by-同舟云学术

Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy

Published:2018-02-12 Issue:7 Volume:26 Page:2471-2477
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Parinyanitikul Napa^ORCID,Tanpipattanakul Walailuk,Poovorawan Nattaya,Rattananupong Thanapoom,Laoitthi Poranee,Sithidetphaiboon Piyada,Thanasanvimon Suebpong,Sriuranpong Virote

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s00520-018-4087-3/fulltext.html

Reference23 articles.

1. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J Clin Oncol 12(12):2654–2666. https://doi.org/10.1200/JCO.1994.12.12.2654

2. McGuire WP et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patient with stage III and IV ovarian cancer. N Engl J Med 344(1):1–6

3. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20(17):3578–3585. https://doi.org/10.1200/JCO.2002.12.112

4. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1997) Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reaction. J Clin Oncol 15(12):3517. https://doi.org/10.1200/JCO.1997.15.12.3517

5. Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF (1996) Carboplatin and paclitaxel in ovarian cancer: a phase I study of Gynecologic Oncology Group. J Clin Oncol 14(6):1895–1902. https://doi.org/10.1200/JCO.1996.14.6.1895

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study;JCO Oncology Practice;2024-09

2. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions;Journal of Oncology Pharmacy Practice;2023-04-06

3. Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer;Cancers;2023-03-09

4. A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Rhizoma Dioscoreae Nipponicae in the Treatment of Asthma;Evidence-Based Complementary and Alternative Medicine;2022-03-30

5. Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis;Supportive Care in Cancer;2022-02-12